| Preferred Name |
Cefotaxime |
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C354 |
| CAS_Registry |
63527-52-6 |
| CHEBI_ID |
CHEBI:204928 |
| Chemical_Formula |
C16H17N5O7S2 |
| code |
C354 |
| Concept_In_Subset | |
| Contributing_Source |
FDA |
| DEFINITION |
A third generation semisynthetic cephalosporin antibiotic with bactericidal activity. Cefotaxime inhibits mucopeptide synthesis by binding to and inactivating penicillin binding proteins thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of bacterial cell walls. This results in a reduction of cell wall stability and causes cell lysis. |
| FDA_UNII_Code |
N2GI8B1GK7 |
| Has_Salt_Form | |
| label |
Cefotaxime |
| Legacy_Concept_Name |
Cefotaxime |
| PDQ_Closed_Trial_Search_ID |
39177 |
| PDQ_Open_Trial_Search_ID |
39177 |
| Preferred_Name |
Cefotaxime |
| prefixIRI |
C354 |
| prefLabel |
Cefotaxime |
| Semantic_Type |
Organic Chemical Antibiotic |
| UMLS_CUI |
C0007554 |
| subClassOf |